Amgen news from FiercePharma
NewsEnbrel gets black-box infection warning
Enbrel's new black box is now official. Wyeth and Amgen have put the final touches on a Read more...
AAMC: Ban pharma gifts at med schools
Will all medical schools bar the door to pharma giveaways? The Association of American Medical Colleges hopes so. After two years of study, the influential group drafted a policy that would ban drug Read more...
AZ, Amgen earnings flat; Shire sales leap
It's a mixed bag of drugmaker earnings reports today, with two biggies posting flat results and two smaller firms chalking up respectable gains.AstraZeneca's profits suffered under restructuring Read more...
Emerging markets drive global growth
Without emerging healthcare markets like China and India, global pharma would be in a world of hurt. The global market for meds reached $712 billion last year, according to a new report from IMS Read more...
Arms twisted, pharma promises disclosure
Pharma knows that self-regulation is the best kind. That's why 12 drug and device makers have promised Sen. Chuck Grassley that they are working on plans to disclose CME grants. You know, the money Read more...
Takeda offers $8.8B for Millennium
Takeda Pharmaceutical is placing an $8.8 billion bet on cancer meds. The Japanese drugmaker has offered $25 per share for Millennium Pharmaceuticals, which not only makes the lucrative blood-cancer Read more...
Roche appeals Mircera injunction
Roche is appealing to a higher power on Mircera. The Swiss drugmaker is appealing a lower court ruling barring Read more...
Grassley: Amgen doc rebates skyrocket
Another day, another Grassley letter. You'll recall that earlier this week, Sen. Chuck Grassley demanded documents from Amgen relating to the company's promotions of its anemia drugs. Now, Grassley Read more...
ALSO NOTED: Takeda prevails in Actos patent suit; Analyst gets peek at Biovail founder's laptop;
> The U.S. Supreme court refused to reconsider an appeals court ruling that upheld Takeda's patent on its diabetes treatment Actos, a decision that keeps Alphapharm from launching a generic Read more...
SPOTLIGHT: Amgen pays CEO 29 percent less
It's a pay cut for Amgen Chairman and CEO Kevin Sharer (photo). His 2007 compensation dropped by nearly 29 percent to Read more...
| Press ReleasesFDA Receives New Data on Risks of Anemia Drugs FDA Receives New Data on Risks of Anemia Drugs Consistent With Previous Data on Tumor Growth and Death The U.S. Food and Drug Administration (FDA) is reviewing new data from two studies that provide Read more... PRESS RELEASE: Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Can Amgen Pivotal Phase 3 Data Show Denosumab Increased Bone Density Throughout Skeleton in Non-Metastatic Breast Cancer Patients on Adjuvant Aromatase Inhibitor Therapy SAN ANTONIO -- Amgen today Read more... PRESS RELEASE: Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Pivotal Phase 3 Romiplostim Study in Splenectomized Patients Meets Primary Endpoints Data Show Romiplostim Increased and Sustained Platelet Counts in Splenectomized Adult Patients with Immune Read more... PRESS RELEASE: Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients Amgen Announces Interim Results of Aranesp ''PREPARE'' Study in Breast Cancer Patients THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received Read more... PRESS RELEASE: FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Mircera (methoxy Read more... |
Get more Amgen coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight